News

There is much to be excited about for 2024. Here's how we are kicking off the New Year at Psychiatric Times.

Examine a case of an adolescent with psychosis that seemed to develop during chemotherapy treatment.

As Martin Luther King Day approaches, a psychiatrist shares his thoughts... and hopes we are in within reach of those dreams and ideals.

APSARD tackles the first US adult ADHD treatment guidelines.

From substance use disorders in physicians to new research on the efficacy of MDMA-assisted therapy for PTSD, here are highlights from the week in Psychiatric Times.

AI is evolving and changing the landscape of medicine and psychiatry. Here’s how clinicians can understand AI’s potential for psychiatry as well as its limitations.

What is new in research on sleep?

RADAR trial finds more relapses when reducing than maintaining antipsychotic, but no difference in social functioning at 2 years.

A dream for social psychiatry, in the vein of Martin Luther King, Jr.

Here's an update on which medications are on the horizon for the treatment of schizophrenia and PTSD.

Take our poll!

What can we learn from war trauma?

Welcome to the intersection of philosophy, psychology, and psychiatry.

In a first of its kind study, MDMA-assisted therapy successfully supported patients with PTSD.

Here are 5 processes to provide focus and empowerment for patients with PTSD.

Knowing the difference between one condition and another is critical, even when the precise diagnosis is unclear.

The challenge for clinicians lies in balancing the profound connection to patients’ suffering with the need to maintain personal resilience.

What did Einstein and Freud have to say about war, and how does it apply today?

The abysmal conditions in state mental hospitals in the 1940s were caused by 3 factors, none of which are now true. Let’s explore.

Travel can boost a clinician’s brain health, cultural intelligence, and creativity.

Here's something we can do physically to prevent suicide.

The ADHD Rx shortage is impacting children and their families. Here, a clinician shares how she supports her patients.

From a groundbreaking new launch for PTSD in the United States to connections between antidepressant treatment and metabolic syndrome, here are highlights from the week in Psychiatric Times.

“If approved, KarXT would represent a new mechanism of action to treat schizophrenia, which would be the first new mechanism potentially in decades.”

What is new in research on posttraumatic stress disorder?

Write to us now to be part of our series focused on clinician wellness this month.

With the upcoming election and the rising risk of COVID, here’s how we can avoid physical and psychological trauma.

New positive pivotal phase 3 study data released on oral weekly risperidone for schizophrenia.